Cancer Genetics — Q1 2016 Earnings Presentation
12 slides from Cancer Genetics's earnings presentation, May 10, 2016
Slide 1: Q1 2016 Earnings Call
May 10, 2016 Q1 2016 Earnings Call Nasdaq (CGIX) THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE
Slide 2: Forward-Looking Statements
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Forward-Looking Statements 2 These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future gro
Slide 3: Everything We Do at CGI Is Focused on One Key Idea
EVERYTHING WE DO AT CGI IS FOCUSED ON ONE KEY IDEA… …DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES IN ONCOLOGY DIAGNOSTICS & PRECISION MEDICINE
Slide 4: Investor Highlights: Cancer Genetics Addresses the Trends in Oncology
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015 Strong & Growing Partnerships with Leading BioPharma CONTRACTS WITH 8 of 1
Slide 5: 1st Quarter 2016 Revenue Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call 1st Quarter 2016 Revenue Highlights 39% REVENUE GROWTHFROM Q1 2015 Q1 TOTAL REVENUE GREW FROM $4.4M TO 2015 2016 $1.4 $4.4 $6.1 $6M $4M $2M 3-Year CAGR 63.3% Q 1 2 0 1 4 Q 1 2 0 1 5 Q 1 2 0 1 6 5
Slide 6: Revenues By Category
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Revenues By Category 6 BIOPHARMA SERVICES CLINICAL SERVICES DISCOVERY SERVICES 76% 20% 4%Q1 2015 $4.4 Mn 245% increase in clinical test volume over Q1 2015 due to Response acquisition and launch of PD-L1 testing Launch of comprehensive
Slide 7: Q1 2016 Trends
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Q1 2016 Trends 7 Validation and launch of comprehensive immuno-oncology portfolio including PD-L1 IHC testing across CGI. Completed clinical validation and launched into a revenue-generating clinical trial utilizing Focus::Oncomine™, a
Slide 8: Q1 2016 Collaboration Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Q1 2016 Collaboration Highlights 8 In 2016, CGI is realizing results from several of its research collaborations with leading academic and research institutions. Huntsman Cancer Institute at University of Utah & Pfizer Dr. Neeraj Argawal
Slide 9: Q1 2016 Financial Highlights: Revenue
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Q1 2016 Financial Highlights: Revenue 9 Revenues were $6.1 million, a 39% increase over Q1 2015 revenues of $4.4 million, and 11% sequentially over Q4 2015. Revenue from Biopharma Services grew 14% ; Clinical Services increased by 3 %;
Slide 10: Q1 2016 Financial Highlights: Expenses
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Q1 2016 Financial Highlights: Expenses 10 Expenses for the quarter were $11.3 million, an 11% improvement over Q4 2015 expenses of $12.7 million. COGS was $4.1 million, a 14% improvement over Q4 2015 and was driven by a reduction in he
Slide 11: Summary Statement of Operations
Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2016 Earnings Call Summary Statement of Operations 11 Income Statement Item ($ in Thousands) Q1 2015 Q4 2015 Q1 2016 Revenue $4,370 $5,484 $6,068 Gross Profit 1,229 728 1,965 Gross Margin (%) 28% 13% 32% Research & Development (R&D) 1,278 1,148 1,532 Sales &
Slide 12: The Oncology Diagnostics Partner from Bench to Bedside
THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE WWW.CGIX.COM WWW.CANCERGENETICS.COM CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 Fax